| Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma |
| Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment |
| Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes |
| Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. |
| A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. |
| Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. |
| Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer |
| . Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer |
| Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. |
| Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. |
| Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil |
| A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer |
| Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. |
| . A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer |
| Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer |
| Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. |
| Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. |
| Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer |
| Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report. |
| Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer |
| A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. |
| A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer |
| Genomic profiling of patient-derived colon cancer xenograft models. |
| Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients. |
| . Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer |
| . Dexamethasone Inhibits TGF-β1-Induced Cell Migration by Regulating the ERK and AKT Pathways in Human Colon Cancer Cells Via CYR61 |
| Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy |
| Skull metastasis of gastric gastrointestinal stromal tumor successfully managed by surgery |
| SCI 등재 전문 학술지 논문 (공동저자) |
| A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. |
| Intrarenal seudoaneurysms complicating renal choriocarcinoma metastases: treatment with coil embolization. |
| Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial. |
| . Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. |
| A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. |
| First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer |
| Changes in quality of life during palliative chemotherapy for solid cancer. |
| Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer |
| J. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. |
| Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. |
| Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cance |
| Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer |
| Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. |
| . Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer |
| Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose |
| A randomized double-blind placebo-controlled study of low-dose intravenous Lorazepam to reduce procedural pain during bone marrow aspiration and biopsy. |
| Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. |
| A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. |
| Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. |
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. |
| Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. |
| A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. |
| Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. |
| Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. |
| Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia. |
| Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer |
| The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control |
| Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer |
| Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. |
| Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone |
| Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. |
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. |
| Pulmonary metastases from colorectal cancer: imaging findings and growth rates at follow-up CT. |
| Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study. |
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. |
| CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. |
| S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. |
| Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. |
| Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. |
| Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. |
| Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. |
| AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. |
| Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. |
| A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. |
| Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. |
| . A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. |
| Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. |
| Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. |
| Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. |
| . S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. |
| Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial |
| A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. |
| Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report. |
| Retrospective analysis of extra-gastrointestinal stromal tumors. |
| Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer |
| Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: |
| Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. |
| SOS study investigators. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS) |
| Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. |
| Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. |
| Efficacy and safety of FOLFIRI regimen in elderly versus nonelderlypatients with metastatic colorectal or gastric cancer |
| Attitudes toward participating in Phase 1 clinical trials: an investigation with patient-family-physician triads. |
| SCI 미등재 전문 학술지 논문 |
| Sheehan증후군에서 복합뇌하수체 자극검사에 대한 뇌하수체전엽홀몬의 동태. |
| 급성골수성 백혈병 및 골수이형성증후군에서 N-ras 암유전자 점돌연변이에 관한 연구 |
| 악성종양에 병발된 미세맥관용혈성빈혈 |
| 비호지킨씨 림프종에서 CAMP-MOB 복합화학요법의 치료효과 |
| 유방암에서 ICE(Ifosfamide, Carboplatin, Etoposide)고용량 화학요법과 자가조혈모세포이식술 |
| 진행성 유방암에서 Vinorelbine, Epirubicin(VE) 복합화학요법 |
| 진행성 비소세포폐암 환자에서 Vinorelbine, Ifosfamide 복합화학요법 |
| 급성골수성 백혈병 환자에서 화학요법과 비경구적 영양요법 중 발생한 베르니케 뇌증 |
| 고위험 유방암환자에서 CPB (Cyclophosphamide, Cisplatin, BCNU)고용량 화학요법과 자가조혈모세포이식술 |
| Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5-Fluorouracil-pretreated patients with metastatic colorectal cancer. |
| Clinical analysis of Phyllodes tumor of the Breast. |
| 급성골수성백혈병에서 AML1/ETO융합유전자와 예후 |
| 급성골수성백혈병에서 Cytarabine과 Idarubicin 관해유도요법 |
| 면역억제치료에 반응을 보인 후천성 무거핵구성혈소판 감소증 1 례 |
| 척추의 압박골절로 발현한 Waldenstrom's Macroglobulinemia 1례 |
| 말기신질환을 동반한 다발성 골수종 1예에서 시행된 자가말초혈액조혈모세포이식 |
| Characteristics of Her-2/neu oncogene in Korean women with early-onset breast cancer by immunohistochemistry and fluorescence in situ hybridization. |
| A phase 11 study of weekly paclitaxel, cisplatin and concurrent radiation therapy for locally-advanced unresectable non-small cell lung cancer:early closure due to lack of efficacy. |
| Prognostic value of AML1/ETO fusion transcripts in patients with acute myelogenous leukemia |
| A phase 11 study of paclitaxel and cisplatin combination chemotherapy in advanced non-small-cell lung cancer. |
| Acute exacerbation of chronic Hepatitis B during thalidomide therapy for multiple myeloma:a case report |
| Clinical features of Waldenstrom macroglobulinemia in Korea |
| Thalidomide in cancer therapy |
| 간세포암 환자에서 doxorubicin과 cisplatin복합화학요법에 대한 제2상 임상연구 |
| 급성관상동맥질환 환자에서 헤파린유도성 혈소판감소증의 빈도와 임상양상에 대한 후향적 고찰 |
| 국한성 소세포폐암에대한 Etoposide(VP-16), Ifosfamide, Carboplatin복합화학요법과 흉부방사선의 동시 병합치료효과 |
| Malignant Gastrointestinal Stromal Tumor in a patient with Neurofibromatosis type 1 |
| 한국인 본태성혈소판혈증환자에서 JAKV617F 유전자병이 |
| 진행성위암에 대한 1차 요법으로 Docetaxel과 Cisplatin 복합화학요법의 효과와 안정성에 대한 연구를 중심으로 |
| Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma |
| 절제불가능한 식도암에서 고선량 외부조사 방사선 치료의 결과 |
| Prolonged extreme thrombocytosis in a postsplenectomy patient with hereditary spherocytosis |
| Additional rituximab-CHOP(R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis |
| Analysis of outcomes and prognostic factors associated with surgical treatment plus post-operative radiation therapy for stage 11/111 pancreatic cancer. |
| 염색체 이상을 동반한 조직구성 수성망상증 1예 |
| 악성 흉막액에 대한 흉막강내 OK-432 주입의 치료효과 |
| 성인급성림프구성 백혈병에서 Vincristine, Prednisolone, Daunorubicin, L-Asparaginase 4제 복합화학요법(VPDL)을 이용한 관해유도 |
